Skip to main content
  • Register
  • Help
  • Contact us

Novavax Inc (NVAX) USD0.01

Sell:$212.63 Buy:$213.01 Change: $4.68 (2.25%)
Market closed |  Prices as at close on 21 April 2021 | Switch to live prices |
Change: $4.68 (2.25%)
Market closed |  Prices as at close on 21 April 2021 | Switch to live prices |
Change: $4.68 (2.25%)
Market closed |  Prices as at close on 21 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Contact details

21 Firstfield Rd
United States
+1 (240) 2682000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$16.36 billion
Shares in issue:
73.86 million
United States
US dollar

Key personnel

  • James Young
    Independent Chairman of the Board
  • Stanley Erck
    President, Chief Executive Officer, Director
  • John Trizzino
    Interim Chief Financial Officer, Executive Vice President, Chief Commercial Officer and Chief Business Officer
  • Gregory Glenn
    President, Research and Development
  • Rick Crowley
    Chief Operating Officer, Executive Vice President
  • Jill Hoyt
    Chief Human Resource Officer, Executive Vice President
  • Troy Morgan
    Executive Vice President, Chief Compliance Officer
  • John Herrmann
    Executive Vice President, Chief Legal Officer and Corporate Secretary
  • Ben Machielse
    Executive Vice President - CMC
  • Frank Czworka
    Senior Vice President - Global Sales

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.